Investing.com - Financial Markets Worldwide
Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Pacific trade negotiators working on medicines deadlock - sources

Published 2015-10-02, 01:28 p/m
© Reuters. Pacific trade negotiators working on medicines deadlock - sources

ATLANTA, Oct 2 (Reuters) - Six Pacific trading partners are
resisting a U.S. push to set rules that would protect patented
next-generation medicines from competition from generic drugs
for eight years and are insisting on a shorter period of five
years as part of a sweeping trade pact, two sources close to the
negotiations said on Friday.
Ministers from the 12 countries negotiating the
Trans-Pacific Partnership entered a third day of talks in
Atlanta still deadlocked over the treatment of biologic drugs,
next-generation drugs which are made from living cells and used
to treat cancer and other diseases.
Monopoly periods for medicines are a sensitive political
issue for countries which face higher public health costs if
cheaper alternatives take longer to come to market.
Pharmaceutical companies argue that increased security for
their intellectual property will encourage investment.
Peru, Chile, Malaysia, New Zealand, Australia and Brunei are
so far sticking to five-year protection periods for biologic
drugs, two sources briefed on the negotiations said.
The United States, which had originally pushed for 12 years,
and countries including Australia and Japan have suggested
possible compromises. Mexico was ready to be flexible depending
on the balance of the negotiations, one source said.
The sources could not be identified due to the sensitivity
of the discussions.
U.S. officials have declined to give details of the
discussions on pharmaceuticals, one of three key issues left to
resolve in talks on the TPP, which would cut trade barriers for
40 percent of the world economy.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.